Evidence map›Paper›PMID 40662637›Full record

ReviewNanomedicine (London, England)2025

Next-generation Nanomaterial-based phototherapeutic strategies for tumor: from NIR responsiveness to smart activation.

Hui Zhang, Xiaoying Tang, Zhenqi Jiang

Abstract readReview
In one paragraph

Review in Nanomedicine (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hui ZhangSchool of Medical Technology, Beijing Institute of Technology Zhengzhou Academy of Intelligent Technology, Beijing Institute of Technology, Beijing, China.
Xiaoying TangSchool of Medical Technology, Beijing Institute of Technology Zhengzhou Academy of Intelligent Technology, Beijing Institute of Technology, Beijing, China.
Zhenqi JiangSchool of Medical Technology, Beijing Institute of Technology Zhengzhou Academy of Intelligent Technology, Beijing Institute of Technology, Beijing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanophototherapy has emerged as a transformative approach in precision oncology, synergistically integrating photodynamic therapy (PDT), photothermal therapy (PTT), and engineered nanomaterials to enhance treatment efficacy. Nevertheless, traditional tumor phototherapy still faces challenges such as insufficient performance of photosensitizers, poor targeting, limited depth of tissue penetration, imprecise thermal control and the complexities of the tumor tumor microenvironment(TME). Addressing these obstacles has driven the evolution of tumor phototherapy toward the development of high-performance near-infrared (NIR) nanomaterials, multimodal synergistic therapies, smart-responsive nanotherapeutic platforms, and biomimetic or biologically derived nanomaterials. This review article focuses on the key advances and representative results achieved by researchers in the above four areas, with an emphasis on analyzing their potentials and challenges in enhancing therapeutic efficacy, modulating delivery, realizing deep therapy, and promoting clinical translation, with the aim of providing new ideas for the future development of nanophototherapy and scholarly research, as well as suggesting the issues that should be paid attention to when researching.

Indexed as

NanostructuresNeoplasmsPhototherapyAnimalsHumansInfrared RaysNanomedicinePhotochemotherapyPhotosensitizing AgentsPhotothermal TherapyTumor MicroenvironmentPhotosensitizing AgentsnanomaterialsNIRPhotodynamic therapyphotothermal therapytumor microenvironment

Identifiers

PMID40662637
PMCPMC12320853

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.